guest ::
| Home > Publications database > EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. > print |
| Home > Publications database > EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. > print |
| 001 | 181427 | ||
| 005 | 20240301125646.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/nox191 |2 doi |
| 024 | 7 | _ | |a pmid:29040782 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5961011 |2 pmc |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a altmetric:27273331 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01995 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Eskilsson, Eskil |b 0 |
| 245 | _ | _ | |a EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. |
| 260 | _ | _ | |a Oxford |c 2018 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1661342849_30652 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a POT Topic: 317 |
| 520 | _ | _ | |a Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need of effective treatment strategies. Recent advances in sequencing techniques unraveled the complete genomic landscape of GBMs and revealed profound heterogeneity of individual tumors even at the single cell level. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Yet, treatment strategies targeting EGFR have thus far failed in clinical trials. In this review, we discuss the clonal and functional heterogeneity of EGFRs in GBM development and critically reassess the potential of EGFRs as therapeutic targets. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Protein Kinase Inhibitors |2 NLM Chemicals |
| 650 | _ | 7 | |a EGFR protein, human |0 EC 2.7.10.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a ErbB Receptors |0 EC 2.7.10.1 |2 NLM Chemicals |
| 650 | _ | 2 | |a ErbB Receptors: antagonists & inhibitors |2 MeSH |
| 650 | _ | 2 | |a ErbB Receptors: genetics |2 MeSH |
| 650 | _ | 2 | |a Glioblastoma: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Glioblastoma: genetics |2 MeSH |
| 650 | _ | 2 | |a Glioblastoma: pathology |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Molecular Targeted Therapy |2 MeSH |
| 650 | _ | 2 | |a Mutation |2 MeSH |
| 650 | _ | 2 | |a Prognosis |2 MeSH |
| 650 | _ | 2 | |a Protein Kinase Inhibitors: therapeutic use |2 MeSH |
| 700 | 1 | _ | |a Røsland, Gro V |b 1 |
| 700 | 1 | _ | |a Solecki, Gergely Morten |0 P:(DE-He78)aceff95b461bf57aaa3c92ea45b28233 |b 2 |
| 700 | 1 | _ | |a Wang, Qianghu |b 3 |
| 700 | 1 | _ | |a Harter, Patrick N |b 4 |
| 700 | 1 | _ | |a Graziani, Grazia |b 5 |
| 700 | 1 | _ | |a Verhaak, Roel G W |b 6 |
| 700 | 1 | _ | |a Winkler, Frank |0 P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b |b 7 |u dkfz |
| 700 | 1 | _ | |a Bjerkvig, Rolf |b 8 |
| 700 | 1 | _ | |a Miletic, Hrvoje |b 9 |
| 773 | _ | _ | |a 10.1093/neuonc/nox191 |g Vol. 20, no. 6, p. 743 - 752 |0 PERI:(DE-600)2094060-9 |n 6 |p 743 - 752 |t Neuro-Oncology |v 20 |y 2018 |x 1522-8517 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:181427 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)aceff95b461bf57aaa3c92ea45b28233 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Translational cancer research |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-02-03 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-02-03 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-03 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2019 |d 2021-02-03 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NEURO-ONCOLOGY : 2019 |d 2021-02-03 |
| 920 | 1 | _ | |0 I:(DE-He78)G370-20160331 |k G370 |l KKE Neuroonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G370-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|